(2-苯并[1,3]二氧代-5-噻唑-4-基)-甲醇 | 248249-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: (2-苯并[1,3]二氧代-5-噻唑-4-基)-甲醇
• 英文名称: 2-(benzo[3,4-d]1,3-dioxolan-5-yl)-4-hydroxymethyl-1,3-thiazole
• 英文别名: (2-Benzo[1,3]dioxol-5-YL-thiazol-4-YL)-methanol；[2-(1,3-benzodioxol-5-yl)-1,3-thiazol-4-yl]methanol
• CAS: 248249-56-1
• 化学式: C₁₁H₉NO₃S
• 分子量: 235.263
• InChiKey: TZLASXJUHCBKSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  (2-苯并[1,3]二氧代-5-噻唑-4-基)-甲醇 、 pyridin-2-ylmethyl methanesulphonate 在 sodium hydride 作用下， 以 四氢呋喃 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 2.0h， 以65%的产率得到2-(benzo[3,4-d]1,3-dioxolan-5-yl)-4-(2-pyridylmethoxymethyl)-1,3-thiazole
  参考文献：
  名称：

  DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES

  摘要：

  公开号：

  EP1073428B1
• 作为产物：
  描述：

  ethyl benzo[d][1,3]dioxole-5-carbimidate 在 manganese(IV) oxide 、 dimethyl sulfide borane 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 32.0h， 生成 (2-苯并[1,3]二氧代-5-噻唑-4-基)-甲醇
  参考文献：
  名称：

  DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES

  摘要：

  公开号：

  EP1073428B1

文献信息

• Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases
  申请人：Choongwae Pharm. Co., Ltd.

  公开号：US20030083326A1

  公开（公告）日：2003-05-01

  The present invention relates to a pharmaceutical composition for the hepatoprotection and treatment of liver diseases comprising as an active ingredient a dihydroxyphenyl derivative represented by the following formula (1), pharmaceutically acceptable acid addition salt or stereochemical isomer thereof together with a pharmaceutically acceptable inert carrier: 1 in which in which A, B, D and E are defined as described in the specification.

  本发明涉及一种用于肝脏保护和治疗肝病的药物组合物，其活性成分为以下式（1）所代表的二羟基苯基衍生物，其药学可接受的酸盐或立体化学异构体，以及药学可接受的惰性载体：其中A、B、D和E如规范中所述定义。
• IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150094297A1

  公开（公告）日：2015-04-02

  The present invention provides thiazole compounds of Formula I wherein W, Y, R 0 , R 2 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 and X 4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了式I的噻唑化合物，其中W、Y、R0、R2、R4、R5、R6、R7、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或其溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。
• Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10428077B2

  公开（公告）日：2019-10-01

  The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了式 I 的噻唑化合物，其中 W、Y、R0、R2、R4、R5、R6、R7、X1、X2、X3 和 X4 如本文所定义，或其立体异构体、同系物、药学上可接受的盐、原药酯或溶 剂形式，其中所有变量如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。
• IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170247395A1

  公开（公告）日：2017-08-31

  The present invention provides thiazole compounds of Formula I wherein W, Y, R 0 , R 2 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 and X 4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
• US6693126B2
  申请人：——

  公开号：US6693126B2

  公开（公告）日：2004-02-17